Neocor secures $3.8M to revolutionize heart valve production by 2027

Neocor, a leader in cardiac prosthetics, has secured 346 million rubles in funding to expand its production. The company dominates nearly half the market for biological heart valves, thanks to decades of innovation. Its latest push focuses on launching transcatheter heart valves by 2027. The company's roots trace back to the 1980s, when Academician Leonid Barbarash founded the bioprosthetics laboratory at Kemerovo Cardiology Center. One of Neocor's earliest breakthroughs came in 1994 with a patented method for preserving biological tissue using epoxy compounds.

Recent advancements include anti-calcification treatments for younger patients and improved thromboresistance in its prostheses. The firm also enhanced antibacterial properties to extend the lifespan of its implants. Now, Neocor aims to produce transcatheter valves at a lower cost than foreign competitors without sacrificing quality.

The 346 million ruble investment includes 80 million from the SME Bank and 100 million in concessional loans from federal and regional Industrial Development Funds. Beyond heart valves, the company plans to diversify into vascular bioprostheses and other biomaterials. Convincing surgeons to adopt the new implants will require ongoing effort, including training and product demonstrations. Regulatory approval remains the next hurdle before Neocor can begin manufacturing transcatheter valves by 2027. The funding will support both production scaling and the development of new biomaterials. If successful, the company's affordable alternatives could reshape the cardiac prosthetics market.